Actively Recruiting
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Led by Tanta University · Updated on 2025-11-25
50
Participants Needed
1
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women
CONDITIONS
Official Title
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 18 years old diagnosed with fatty liver by upper abdominal ultrasound
You will not qualify if you...
- Pregnant or breastfeeding women
- Excessive alcohol use: over 30 g/day for men or over 20 g/day for women
- Other chronic liver diseases such as viral hepatitis, drug-induced hepatitis, or autoimmune hepatitis
- Chronic kidney disease
- Hyperparathyroidism or hypoparathyroidism
- Congestive heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mostafa Bahaa
Damietta, New Damietta, Egypt, 34518
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here